Black box top

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

error: Alert: Content is protected !!

Considerations for Prescribing SGLT2i Therapy in Type 2 Diabetes Mellitus

The clinical summary below aims to offer practical advice for healthcare professionals when prescribing SGLT2i therapies for the treatment of T2DM. Please refer to the relevant individual SmPC before prescribing any SGLT2i therapy: Canagliflozin | Dapagliflozin | Empagliflozin | Ertugliflozin

Considerations for Prescribing SGLT2i Therapy in Type 2 Diabetes Mellitus

The clinical summary below aims to offer practical advice for healthcare professionals when prescribing SGLT2i therapies for the treatment of T2DM. Please refer to the relevant individual SmPC before prescribing any SGLT2i therapy: Canagliflozin | Dapagliflozin | Empagliflozin | Ertugliflozin

Considerations for Prescribing SGLT2i Therapy in Type 2 Diabetes Mellitus

The clinical summary below aims to offer practical advice for healthcare professionals when prescribing SGLT2i therapies for the treatment of T2DM. Please refer to the relevant individual SmPC before prescribing any SGLT2i therapy: Canagliflozin | Dapagliflozin | Empagliflozin | Ertugliflozin

Considerations for Prescribing SGLT2i Therapy in Type 2 Diabetes Mellitus

The clinical summary below aims to offer practical advice for healthcare professionals when prescribing SGLT2i therapies for the treatment of T2DM. Please refer to the relevant individual SmPC before prescribing any SGLT2i therapy: Canagliflozin | Dapagliflozin | Empagliflozin | Ertugliflozin

Considerations for Prescribing SGLT2i Therapy in Type 2 Diabetes Mellitus

The clinical summary below aims to offer practical advice for healthcare professionals when prescribing SGLT2i therapies for the treatment of T2DM. Please refer to the relevant individual SmPC before prescribing any SGLT2i therapy: Canagliflozin | Dapagliflozin | Empagliflozin | Ertugliflozin

Considerations for Prescribing SGLT2i Therapy in Type 2 Diabetes Mellitus

The clinical summary below aims to offer practical advice for healthcare professionals when prescribing SGLT2i therapies for the treatment of T2DM. Please refer to the relevant individual SmPC before prescribing any SGLT2i therapy: Canagliflozin | Dapagliflozin | Empagliflozin | Ertugliflozin

Considerations for Prescribing SGLT2i Therapy in Type 2 Diabetes Mellitus

The clinical summary below aims to offer practical advice for healthcare professionals when prescribing SGLT2i therapies for the treatment of T2DM. Please refer to the relevant individual SmPC before prescribing any SGLT2i therapy: Canagliflozin | Dapagliflozin | Empagliflozin | Ertugliflozin

Considerations for Prescribing SGLT2i Therapy in Type 2 Diabetes Mellitus

The clinical summary below aims to offer practical advice for healthcare professionals when prescribing SGLT2i therapies for the treatment of T2DM. Please refer to the relevant individual SmPC before prescribing any SGLT2i therapy: Canagliflozin | Dapagliflozin | Empagliflozin | Ertugliflozin

Considerations for Prescribing SGLT2i Therapy in Type 2 Diabetes Mellitus

The clinical summary below aims to offer practical advice for healthcare professionals when prescribing SGLT2i therapies for the treatment of T2DM. Please refer to the relevant individual SmPC before prescribing any SGLT2i therapy: Canagliflozin | Dapagliflozin | Empagliflozin | Ertugliflozin

Considerations for Prescribing SGLT2i Therapy in Type 2 Diabetes Mellitus

The clinical summary below aims to offer practical advice for healthcare professionals when prescribing SGLT2i therapies for the treatment of T2DM. Please refer to the relevant individual SmPC before prescribing any SGLT2i therapy: Canagliflozin | Dapagliflozin | Empagliflozin | Ertugliflozin

Dapagliflozin | Dose | Safety | Side-effects | NICE
Indication: T2D glycaemic control
↓eGFR: ≥ 45 = 10mg| < 45 = not recommended for glycaemic control
Indication: Chronic HFrEF with or without T2D
↓eGFR: ≥ 15 = 10mg| < 15 = Continue but don't initiate
Indication: Chronic Kidney Disease with or without T2D
↓eGFR: ≥ 15 = 10mg| < 15 = Continue but don't initiate

SOURCE: @Visualmedapp

Dapagliflozin | Dose | Safety | Side-effects | NICE
Indication: T2D glycaemic control
↓eGFR: ≥ 45 = 10mg| < 45 = not recommended for glycaemic control
Indication: Chronic HFrEF with or without T2D
↓eGFR: ≥ 15 = 10mg| < 15 = Continue but don't initiate
Indication: Chronic Kidney Disease with or without T2D
↓eGFR: ≥ 15 = 10mg| < 15 = Continue but don't initiate

SOURCE: @Visualmedapp

Canagliflozin | Dose | Safety | Side-effects | NICE
Indication: T2D glycaemic control
↓eGFR: ≥ 60 = 100mg, titrate → 300mg if required | 45 - 59 = Use 100mg only | < 45 = not recommended for glycaemic control
Indication: T2D + Diabetic Kidney Disease
↓eGFR: ≥ 30 = Initiate and continue 100mg | < 30* = Continue but do not initiate 100mg | Dialysis = STOP
*With urinary albumin/creatinine ratio > 30 mg/mol

SOURCE: @Visualmedapp

Empagliflozin | Dose | Safety | Side-effects | NICE
Indication: T2D glycaemic control
↓eGFR: ≥ 60 = Initiate 10mg, titrate → 25mg if required | 45 - 60 = Continue 10mg only but do not initiate | < 45 = STOP
Indication: T2D AND estalished cardiovascular disease
↓eGFR: ≥ 60 = Initiate 10mg, titrate → 25mg if required | 30 - 60 = Initiate or continue 10mg only | < 30 = STOP
Indication: Chronic HFrEF with or without T2D
↓eGFR: ≥ 20 = Initiate or continue 10mg | < 20 = STOP

SOURCE: @Visualmedapp

Ertugliflozin | Dose | Safety | Side-effects | NICE
↓eGFR: Initiate only if eGFR ≥ 60 = 5mg, titrate → 15mg if required | < 45 = STOP

SOURCE: @Visualmedapp

Empagliflozin | Dose | Safety | Side-effects | NICE
Indication: T2D glycaemic control
↓eGFR: ≥ 60 = Initiate 10mg, titrate → 25mg if required | 45 - 60 = Continue 10mg only but do not initiate | < 45 = STOP
Indication: T2D AND estalished cardiovascular disease
↓eGFR: ≥ 60 = Initiate 10mg, titrate → 25mg if required | 30 - 60 = Initiate or continue 10mg only | < 30 = STOP
Indication: Chronic HFrEF with or without T2D
↓eGFR: ≥ 20 = Initiate or continue 10mg | < 20 = STOP

SOURCE: @Visualmedapp

Dapagliflozin | Dose | Safety | Side-effects | NICE
Indication: T2D glycaemic control
↓eGFR: ≥ 45 = 10mg| < 45 = not recommended for glycaemic control
Indication: Chronic HFrEF with or without T2D
↓eGFR: ≥ 15 = 10mg| < 15 = Continue but don't initiate
Indication: Chronic Kidney Disease with or without T2D
↓eGFR: ≥ 15 = 10mg| < 15 = Continue but don't initiate

SOURCE: @Visualmedapp

Canagliflozin | Dose | Safety | Side-effects | NICE
Indication: T2D glycaemic control
↓eGFR: ≥ 60 = 100mg, titrate → 300mg if required | 45 - 59 = Use 100mg only | < 45 = not recommended for glycaemic control
Indication: T2D + Diabetic Kidney Disease
↓eGFR: ≥ 30 = Initiate and continue 100mg | < 30* = Continue but do not initiate 100mg | Dialysis = STOP
*With urinary albumin/creatinine ratio > 30 mg/mol

SOURCE: @Visualmedapp